ArticleFrontiers in cellular and infection microbiology2022
Molecular Characteristics of Regional Chromoblastomycosis in Guangdong, China: Epidemiological, Clinical, Antifungal Susceptibility, and Serum Cytokine Profiles of 45 Cases.
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026Article
- Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies.Current fungal infection reports · 2026Article
- Inhibitory effects of berberine on Fonsecaea monophora in vitro and in vivo.BMC complementary medicine and therapies · 2025Article
- Bridging gaps in the elimination of deep mycoses: a comparative analysis of mycetoma and chromoblastomycosis control strategies in Rwanda and China.Tropical medicine and health · 2025Review
- Absence of neutrophils impairs the host defense in murine footpad model of chromoblastomycosis.PLoS neglected tropical diseases · 2025Article
- Cost-effective in-house-made whole blood materials for internal quality control in clinical flow cytometry analysis.Analytical and bioanalytical chemistry · 2025Article
- Antifungal Susceptibility of Melanized Fungi Isolated from CARD9 Deficient Patients: Implications for Treatment of Refractory Infections.Mycopathologia · 2025Article
- Development of PCR-Multiplex Assays for Identification of the Herpotrichiellaceae Family and Agents Causing Chromoblastomycosis.Journal of fungi (Basel, Switzerland) · 2024Article
- Successful management of chromoblastomycosis utilizing conventional antifungal agents and imiquimod therapy.Annals of clinical microbiology and antimicrobials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromoblastomycosis (CBM) is a chronic disease caused by several species of dematiaceous fungi. In this study, a regional collection of 45 CBM cases was conducted in Guangdong, China, a hyper-endemic area of CBM. Epidemiology findings indicated that the mean age of cases was 61.38 ± 11.20 years, long duration ranged from 3 months to 30 years, and the gender ratio of male to female was 4.6:1. Thirteen cases (29%) declared underlying diseases. Verrucous form was the most common clinical manifestation (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.